Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosbretabulin and Everolimus in Neuroendocrine Tumors
NCT03014297Phase 1Terminated
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosbretabulin in Neuroendocrine Neoplasm (NEN). Started Mar 2017; status: terminated.
02
Drugs
fosbretabulin
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03014297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03014297.